Jasper Therapeutics’ anti-c-KIT antibody has shown promise in a Phase 1b/2a test in people with certain irritable skin conditions, sending its shares rising on Monday …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.